179 related articles for article (PubMed ID: 20059562)
21. Prolonged effect of a new O-glycoPEGylated FVIII (N8-GP) in a murine saphenous vein bleeding model.
Pastoft AE; Ezban M; Tranholm M; Lykkesfeldt J; Lauritzen B
Haemophilia; 2013 Nov; 19(6):913-9. PubMed ID: 23730746
[TBL] [Abstract][Full Text] [Related]
22. Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A.
Mullins ES; Stasyshyn O; Alvarez-Román MT; Osman D; Liesner R; Engl W; Sharkhawy M; Abbuehl BE
Haemophilia; 2017 Mar; 23(2):238-246. PubMed ID: 27891721
[TBL] [Abstract][Full Text] [Related]
23. PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers.
Ivens IA; Baumann A; McDonald TA; Humphries TJ; Michaels LA; Mathew P
Haemophilia; 2013 Jan; 19(1):11-20. PubMed ID: 22913770
[TBL] [Abstract][Full Text] [Related]
24. Strategies towards a longer acting factor VIII.
Saenko EL; Pipe SW
Haemophilia; 2006 Jul; 12 Suppl 3():42-51. PubMed ID: 16683996
[TBL] [Abstract][Full Text] [Related]
25. Optimizing factor prophylaxis for the haemophilia population: where do we stand?
Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R
Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380
[TBL] [Abstract][Full Text] [Related]
26. The first recombinant FVIII produced in human cells--an update on its clinical development programme.
Valentino LA; Negrier C; Kohla G; Tiede A; Liesner R; Hart D; Knaub S
Haemophilia; 2014 Jan; 20 Suppl 1():1-9. PubMed ID: 24330348
[TBL] [Abstract][Full Text] [Related]
27. Passive transfer of polyethylene glycol to liposomal-recombinant human FVIII enhances its efficacy in a murine model for hemophilia A.
Ramani K; Purohit V; Miclea R; Gaitonde P; Straubinger RM; Balu-Iyer SV
J Pharm Sci; 2008 Sep; 97(9):3753-64. PubMed ID: 18300296
[TBL] [Abstract][Full Text] [Related]
28. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
Ahnström J; Berntorp E; Lindvall K; Björkman S
Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
[TBL] [Abstract][Full Text] [Related]
29. AHEAD. Advate in HaEmophilia A outcome Database.
Oldenburg J; Kurnik K; Huth-Kühne A; Zimmermann R; Abraham I; Klamroth R
Hamostaseologie; 2010 Nov; 30 Suppl 1():S23-5. PubMed ID: 21042659
[TBL] [Abstract][Full Text] [Related]
30. Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy.
Baru M; Carmel-Goren L; Barenholz Y; Dayan I; Ostropolets S; Slepoy I; Gvirtzer N; Fukson V; Spira J
Thromb Haemost; 2005 Jun; 93(6):1061-8. PubMed ID: 15968389
[TBL] [Abstract][Full Text] [Related]
31. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy.
Lentz SR; Misgav M; Ozelo M; Salek SZ; Veljkovic D; Recht M; Cerqueira M; Tiede A; Brand B; Mancuso ME; Seremetis S; Lindblom A; Martinowitz U
Haemophilia; 2013 Sep; 19(5):691-7. PubMed ID: 23647704
[TBL] [Abstract][Full Text] [Related]
32. Clinical evaluation of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A.
Fukui H; Yoshioka A; Shima M; Tanaka I; Koshihara K; Fukutake K; Fujimaki M
Int J Hematol; 1991 Oct; 54(5):419-27. PubMed ID: 1756252
[TBL] [Abstract][Full Text] [Related]
33. The role of VWF in the immunogenicity of FVIII.
Lacroix-Desmazes S; Repessé Y; Kaveri SV; Dasgupta S
Thromb Res; 2008; 122 Suppl 2():S3-6. PubMed ID: 18549909
[TBL] [Abstract][Full Text] [Related]
34. Novel therapies for immune tolerance in haemophilia A.
Collins PW
Haemophilia; 2006 Dec; 12 Suppl 6():94-100; discussion 100-1. PubMed ID: 17123401
[TBL] [Abstract][Full Text] [Related]
35. Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia A.
Wolf DM; Rokicka-Milewska R; Lopaciuk S; Skotnicki AB; Klukowska A; Laguna P; Windyga J; Kotitschke R; Struff WG
Haemophilia; 2004 Sep; 10(5):438-48. PubMed ID: 15357768
[TBL] [Abstract][Full Text] [Related]
36. Comparing prophylaxis with episodic treatment in haemophilia A: implications for clinical practice.
Manco-Johnson M
Haemophilia; 2007 Sep; 13 Suppl 2():4-9. PubMed ID: 17685917
[TBL] [Abstract][Full Text] [Related]
37. Low risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell-produced to baby hamster kidney cell-produced recombinant factor VIII.
Singleton E; Smith J; Kavanagh M; Nolan B; White B
Thromb Haemost; 2007 Dec; 98(6):1188-92. PubMed ID: 18064312
[TBL] [Abstract][Full Text] [Related]
38. Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A mice.
Pan J; Liu T; Kim JY; Zhu D; Patel C; Cui ZH; Zhang X; Newgren JO; Reames A; Canivel D; Jesmok G; Pierce GF; Sommer JM; Jiang H
Blood; 2009 Sep; 114(13):2802-11. PubMed ID: 19654409
[TBL] [Abstract][Full Text] [Related]
39. Report on 4 cases with decreased recovery due to neutralizing antibodies specific for PEGylated recombinant factor VIII.
Hillarp A; Holme PA; Wåland EP; Le MS; Henriksson CE; Tjønnfjord GE; Måseide RJ
J Thromb Haemost; 2023 Oct; 21(10):2771-2775. PubMed ID: 37543216
[TBL] [Abstract][Full Text] [Related]
40. Real-world experience with use of Antihemophilic Factor (Recombinant), PEGylated for prophylaxis in severe haemophilia A.
Dunn AL; Ahuja SP; Mullins ES
Haemophilia; 2018 May; 24(3):e84-e92. PubMed ID: 29359417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
